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comparison had a lower P-value and had a higher degree
of deregulation than the differentially expressed genes from
the comparison TET2 mutated versus wild type (Figure 1 b;
Supplementary Figure 1 and Supplementary Tables 2 and 3).
These results indicate that 5hmC levels are most likely a more
relevant measurement to define biologically distinct secondary
leukemia subtypes than the TET2 (or IDH1/2) mutational status.
The fact that in some patient samples with low 5hmC levels
neither TET2 nor IDH1/2 mutations could be identified suggests
that additional genes might be directly or indirectly involved in
the regulation of 5hmC levels. To further elucidate the
regulation of 5hmC levels and their role in leukemogenesis,
larger groups of sAML as well as de novo AML patients need
to be studied.
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B-cell precursor acute lymphoblastic leukemia
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Neoplasms often display significant heterogeneity in morpho-
logy, gene expression (including cell surface markers), genetic
aberrations, cell proliferation kinetics and response to therapy.1
Heterogeneity in antigen marker expression is well known in
acute myeloid leukemia (AML);2 however, has rarely been
studied in acute lymphoblastic leukemia (ALL). In ALL, shifts in
immunophenotypic and genetic profiles can occur between
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diagnosis and relapse.3 Such changes of immune gene-
rearrangement profiles can reflect the presence at diagnosis of
minor, but genomically distinct sub-populations.4 Likewise,
changes in immunophenotype might reflect phenotypically
distinct sub-populations at diagnosis that potentially could
be detected in a more sensitive flow-cytometric analysis than
used routinely. If such sub-populations are present and different
immunophenotypes are related to differences in gene rearrange-
ment profiles, this could cause discordances between the
methods for minimal residual disease (MRD) monitoring,
that is, flow-cytometric immunophenotyping and PCR-based
detection of clonotypic immunoglobulin (Ig)/T-cell receptor
(TCR) gene rearrangements. Importantly, sub-populations
are also relevant for the understanding of the ontogenesis
of the malignant cells and might give clues for under-
standing the biological mechanisms of therapy resistance and
relapse.
In this study, we explored the presence at diagnosis of
immunophenotypically heterogeneous leukemic cell popula-
tions, that is, distinct sub-populations with bimodal marker
expression or populations with broad marker expression,
in childhood B-cell precursor (BCP) ALL. Immunopheno-
typically heterogeneous cells were isolated by flow sorting
and investigated for the clone-defining cytogenetic marker
and a broad spectrum of clonal Ig/TCR gene rearrange-
ments.
We studied 40 bone marrow (BM) samples and one peripheral
blood sample obtained at diagnosis from 41 consecutive
patients, with childhood (below 18 years of age) BCP-ALL
diagnosed from March 2008 to July 2009. Three patients
diagnosed during this time period could not be included due
to lack of diagnostic samples (two patients) or lack of flow data
(one patient). One additional patient diagnosed in October
2009, who had immunophenotypically distinct sub-populations,
was included only in the cytogenetic/molecular analysis. The
diagnosis was established according to the conventional criteria.
In all, 39 of the patients were enrolled in the Nordic
Organization for Pediatric Hematology and Oncology
(NOPHO) ALL-2000 or NOPHO ALL-2008 treatment protocols.
Two infant patients were enrolled in the Interfant-06 protocol. In
ALL-2000, BM samples were obtained from patients admitted to
The University Hospital Rigshospitalet, Copenhagen (account-
ing for approximately half of Danish patients), whereas in
ALL-2008, samples were obtained from all Danish patients.
Samples were collected in heparin-RPMI1640 and processed
within 24 h of collection. All patients/parents gave informed
consent to participate in this study according to the guide-
lines of the Danish Ethics Committee (HC-2008-081 and 2001-
10205).
Samples for FC analysis were subjected to Lymphoprep
separation of mononuclear cells. Staining for flow-cytometric
immunophenotyping was performed with standard procedures
according to the NOPHO guidelines. Data acquisition was
performed on FACSAria cytometer equipped with the FACS
Diva 6 software (Becton Dickinson, San Jose, CA, USA). A
minimum of 100 000 events was acquired. Dead cells and
debris were excluded in forward scatter (FSC)/side scatter (SSC)
dot plots based on propidium-iodide staining. Aggregated cells
were excluded based on FSC height versus FSC area dot plots.
BCP blast populations were identified using CD45/CD19 dot
plots. By using backgating into FSC/SSC plots, we verified that
minor sub-populations were always located in the region where
viable blasts are normally found.
Immunophenotypic marker expression on blast populations
was given a score as negative (), positive dim (þ ), positive
normal (þ þ ) or positive bright (þ þ þ ), as compared with the
expression on normal precursor B cells. Normal BM samples
were analyzed in parallel using the same flow-cytometry
settings. Antigens not expressed by normal precursors were
only scored as negative or positive. Only antigen markers
normally expressed by precursors were scored referring to
the normal expression. Special attention was given to dim
populations, which were defined as positive dim when more
than 20% of the population was brighter than the corresponding
isotype control. Distinct sub-populations were defined as
separate populations, each having their own peak in contour
plots (In FACSDiva 6; resolution: 128, percentage: 10) and
histograms (described as bimodal expression). The size limit to
what was named sub-populations was set to 42% of total blast
count, as populations smaller than this were difficult to classify
by our FC setup (4- or 6-color and 100000 cells analyzed). We
defined broad expression of a marker to occur when
a population that only has one peakFusing the outer line of
the 10% contour plot as boundaryFextends from one score into
the middle of the neighboring score.
Patients from the ALL-2000 protocol were analyzed using the
following protocol-defined four-color combinations: CD45/
CD34/CD19/CD10; CD10/CD20/CD19/CD45; CD34/CD22/
CD19/CD45; CD34/CD38/CD19/CD45; TdT/CD10/CD19/CD45.




Fluorochromes in the four channels were: FITC/PE/PC5/APC,
respectively.
Patients from ALL-2008 protocol were analyzed with the
protocol-defined six-color combinations:CD10/CD20/CD34/
CD19/CD38/CD45; CD66c/CD123/CD34/CD19/CD22/CD45; TdT/




Fluorochromes in the channels were: FITC/PE/PerCP-Cy5.5/
PE-Cy7/APC/APC-Cy7, respectively. The following abbreviations
are used: cy, cytoplasmic; kappa, Ig kappa light chain;
lambda, Ig lambda light chain; TdT, terminal deoxynucleotidyl
transferase; HLA, human leukocyte antigen.
Flow sorting was performed on FACSAria (Becton
Dickinson). Sorting was carried out in ‘high speed’ with a
70-mm nozzle, sheath pressure of 70 PSI and sort precision
mode set to ‘Purity’. When feasible with respect to sample size
and cell number, a part of the sorted populations were
reanalyzed, showing a sorting purity of minimum 98%. Cells
for fluorescence in situ hybridization (FISH) analysis were
sorted onto polylysine-coated glass slides into a droplet
(50–100 ml) of phosphate-buffered saline or CytoFix (Becton
Dickinson) placed on the slide. When cells were not fixated
before sorting and sorted into a phosphate-buffered saline
droplet, the cells on the slides were fixated in methanol/glacial
acid (3:1). Fixated slides were dehydrated and then kept
at –201C for later FISH analysis. Cells to be analyzed by PCR
were sorted into eppendorf tubes containing 500 ml RPMI
medium, and cell pellets were kept at 80 1C for later DNA
purification.
As part of the diagnostics for childhood ALL, chromosome
analyses (G-banding) and FISH were carried out on diagnostic
BM samples of all ALL patients. The applied FISH probes
were MLL dual color, break apart rearrangement probe,
TCF3/PBX1 dual color, dual fusion probe, BCR/ABL dual color,
dual fusion probe, EVT6/RUNX1(TEL/AML1) ES dual color
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probe (all probes from Vysis, Abbott, Weisbaden, Germany).
Patients with a normal or failed karyotype were in addition
screened with FISH probes for chromosomes 4, 10 and 17
(CEP4, CEP10, CEP17, Vysis, Abbott). The flow-sorted cell
populations were analyzed for the clone-defining FISH marker
using a selected FISH probe in each patient (for details, see
Supplementary Table). FISH was performed according to
standard procedures. At least 50 nuclei were analyzed when
possible.
DNA from the sorted-cell populations was purified by the
SpinTissue XS kit (Macherey-Nagel, Du¨ren, Germany) and
eluted in 30 ml H2O. As the PCR clonality assay requires larger
amount of DNA, we used whole-genome amplified DNA as
template. Whole-genome amplification (WGA) was performed
using REPLI-g Mini Kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions, with a minimum of B10-ng
input DNA to minimize amplification bias. WGA was performed
on DNA from both unsorted and sorted specimens, and
amplified DNA (WGA-DNA) was purified using the QIAamp
DNA Mini Kit (Qiagen). WGA-DNA from sorted-cell popula-
tions was analyzed for the presence of a broad spectrum of
clonal Ig and TCR gene rearrangements (IGH VH-JH, IGH DH-JH,
IGK V-Kde/intronRSS-Kde, TCRB Vb-Jb, TCRB Db-Jb, TCD and
TCRG) using the IdentiClone Clonality Assays (InVivoScribe
Technologies, San Diego, CA, USA). The gene loci studied
covers the majority of all possible gene rearrangements. All the
Ig/TCR gene loci were analyzed in each unsorted BM samples
and in flow-sorted each cell population. For each patient, the
gene rearrangement profiles were compared between: genomic
DNA from unsorted sample, WGA-DNA from unsorted sample
and WGA-DNA from sorted subfractions. GeneScanning of PCR
products were performed by capillary electrophoresis (3130
Genetic Analyzer, Carlsbad, CA, USA). In cases where
unexpected clonal products were found, the WGA and PCR
were repeated for verification of the findings.5
Analyzing the expression of the 14 antigen markers (CD10,
CD34, CD38, CD45, TdT, HLA-DR, CD19, CD20, CD22,
cyCD22, cyCD79a, lambda, kappa and cyIgM), we observed
immunophenotypically distinct sub-populations defined by their
bimodal antigen expression in more than half (27/41) of the
patients studied (Table 1 and Figure 1). The sub-populations
were most commonly characterized by a bimodal expression
of CD34 (18/41 patients) and of TdT (11/41 patients), but five
patients showed bimodal expression of both CD34 and TdT.
Few examples of bimodal expression of other markers were also
observed: for example, CD10 (two patients), CD45 (two
patients) and lambda (two patients). The sub-populations often
comprised more than 10% of the total blast count, seen in 15 of
the 18 patients with bimodal CD34 expression and in 6 of the 11
patients with bimodal TdT expression. In the cases with bimodal
CD34 expression, it was random whether the major population
had the highest or lowest expression. In contrast, in almost all of
the cases with bimodal TdT expression (10 cases out of 11),
the major population had the highest TdT expression, being
positive normal in all cases.
Broad expression, as defined above, of one or more markers
was observed in almost all patients, that is, 38/41 of the
patients studied. The markers involved were most commonly
CD20 (23 patients), CD45 (14 patients) and TdT (13 patients)
(Table 1). The broad expression patterns were verified by
single-color FC in seven representative cases (three
CD20broad, two TdTbroad and two CD34broad) from five
BM samples. There was no tendency that broad expression of
one marker was specifically correlated to broad expression
of another specific marker.
In 15 of the patients in whom distinct sub-populations
or broad expression emerged, the immunophenotypically
heterogeneous populations were isolated by flow sorting for
subsequent genomic analyses (Figure 2). As the cytogenetic
abnormalities are considered a primary event in leukemogenesis,
we analyzed the flow-sorted populations by FISH to verify the
malignant state of the cells. We found that all flow-sorted
presumed leukemic cell populations showed similar dominance
of cytogenetic aberrant cells by having 60–100% FISH-positive
cells (29 populations from 10 patients), irrespective of bimodal
or broad expression of the defining marker. In the remaining
five patients, we did not obtain FISH results due to bad quality of
the cells or lack of a FISH marker. Expected normal cell
populations with normal immunophenotype (six populations
from five patients) had normal karyotype (92–100%
FISH-negative cells).
Screening each flow-sorted cell population (37 suspected
leukemic and 12 expected normal cell populations from 15
patients) for a broad spectrum of Ig/TCR targets, we found that in
14 out of the 15 patients analyzed, the unsorted sample and all
sorted expected leukemic subfractions (36) shared identical
patterns of clonal gene rearrangements (Figure 2): Clonal Ig/TCR
gene rearrangements detected in the unsorted specimen were
also detected in all malignant subfractions at similar signal
intensities when analyzing equal amounts of DNA. In unsorted
specimens with polyclonal normal rearrangements, no clear
clonal products were subsequently detected in sorted leukemic
subfractions. One patient, however, had a distinct Ig/TCR gene
rearrangement profile in one sub-population. This patient
showed two clonal IGH-VJ rearrangements in a population of
CD34dim cells, but only one clonal product in the
CD34normal cells. Both of these populations had an immuno-
phenotype consistent with common BCP-ALL. Loss of one
marker in one sub-population may be due to secondary
rearrangements or deletion of a chromosomal segment (genomic
instability affecting this gene locus), as has been suggested
in cases of loss of IG/TCR markers at relapse.
Table 1 Number of patients showing bimodal and/or broad
expression of the analyzed markers






CD34 18/41 (7) 8/41 (4)
TdT 11/41 (1) 13/41
CD10 2/41 (2) 10/41
CD45 2/41 (1) 14/41
Lambda 2/41 (2) 0/41
CD22 1/41 4/41
CD66c 2/25 3/25




The following markers were also analyzed: CD19 (41 patients),
cyCD22 (41 patients), HLA-DR (41 patients), CD33 (41 patients),
kappa (41 patients), cyIgM (41 patients), CD13 (41 patients), CD2
(31 patients), CD7 (39 patients) and CD133 (10 patients), but no cases
of bimodal expression of these markers were observed, and broad
expression was observed in none or less than 10% of patients
analyzed.
aNumbers in parentheses show number of patients in whom the
immunophenotypically heterogeneous cell populations were isolated
by flow sorting.
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Cell populations regarded to be normal were analyzed in nine
patients. In six of these patients with clear separation between
immunophenotype-defined normal and malignant cells, the
flow-sorted normal cells had normal IG/TCR polyclonal profiles.
In two patients, normal cells were incompletely separated from













Gated on Q2+Q4 (CD10++)
Gated on Q1+Q2 (CD20+)
Gated on Q3+Q4 (CD10-)Gated on Q1+Q2 (CD10++)
Gated on Q1+Q3 (cTdT+)
Gated on Q3+Q4 (CD20-)
Gated on Q1+Q3 (CD10-)
Gated on Q2+Q4 (cTdT++)
Figure 1 Examples of heterogeneous antigen expression at diagnosis in BCP-ALL. The left hand dot plots (a) are all gated on cells with blast FSC/
SSC characteristics, while the right hand plots (b) are further gated on CD19-positive cells. Green color denotes leukemic cells; and red color
denotes normal mature B cells. The histograms (c) are gated on the CD19-positive leukemic cells. (A) Examples of bimodal and broad expression of
CD34. (B) Examples of simultaneous bimodal/broad expression of two markers in one antibody combination. Histograms (c) are gated on selected
fractions of leukemic cells as described below each plot.
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cells classified as normal of the same clonal immune-gene
markers as identified in the leukemic cells. In one patient, we
found a distinct clonal profile in the presumed normal mature B
cells. This patient (classified as infant on the basis of the age at
diagnoses, but with typical BCP-ALL phenotype and
without MLL rearrangement) who presented with two distinct
CD34negative/CD34normal sub-populations, had a clonal IGH
V-J product in the expected normal cells that was not present in
any of the leukemic sub-populations. We cannot determine
whether this reflects a normal lymphocyte population under-
going an immune response with oligoclonal proliferation or a
leukemic subclone. Another clonal IGH V-J product was
identified in the leukemic cells and this was not present in the
presumed normal mature B cells.
Our finding of one case with absence of one of the
dominating clonal PCR markers suggests that this could lead
to misjudgment of MRD, and the use of at least two independent
markers in real-time quantitative PCR-based MRD analyses may
reduce the risk of such false conclusions.
In ALL, several studies have focused on genomic hetero-
geneity and the genetic basis of relapse by comparing genomic
profiles in paired diagnosis and relapse samples. It is
hypothesized that outgrowth of therapy-resistant subclones,
genomically distinct from the predominant clone and present
already at diagnosis, is the mechanism of therapy resistance
and relapse in the majority of ALL relapse cases. This
hypothesis is supported by the finding that in some relapsed
patients new Ig/TCR gene rearrangements were detected at
relapse and that these ‘relapse clones’ could be detected at
diagnosis using more sensitive methods than those used
routinely.4 Although restricted to sub-populations accounting
for at least 2% of the total number of leukemic cells, our
findings show that the immunophenotypically distinct sub-
populations in general do not define clones with distinct
rearrangements. Backtracking of relapse clones by sensitive
PCR analyses in flow-sorted cell populations in stored
diagnostic samples could specify in which immunophenotypi-
cally defined population(s) these cells would be found. Another
important question is whether the immunophenotypically
distinct sub-populations have different in vivo leukemia-
initiating capacity or different sensitivity toward therapy,
as indicated by studies of sub-populations differing in CD34
expression.6
The observed bimodal expression and broad expression of
antigen markers in BCP-ALL could reflect two different
biological phenomena, respectively. The observed broad
expression patterns of some markers, for example CD20,
resemble the maturation spectrum seen in normal precursor
B cells.7 Thus, it is likely that it reflects partial maturation of the
blastsFresembling the phenotypic heterogeneity seen in AML.
In AML, there is increasing evidence that immunophenotypi-
cally distinct leukemic cells are also functionally heterogeneous
and that rare sub-populations of leukemia-initiating cells exists.
It is thought that AML, like the normal hematopoietic system,
is organized as a hierarchy of distinct cell classes, sustained by a
subset of leukemic stem cells that alone have long-term
repopulating potential and give rise to progeny that lack this
potential.8
It is recognized that immunophenotypic modulations of
leukemic cells frequently occur during early treatment, possibly
induced by the steroids used in induction therapy.9
We observed a marked overlap between markers with broad
expression at diagnosis and markers typically modulated during
treatment. Thus, the broad expression at diagnosis might
be related to physiological stress factors released during overt
disease.
Bimodal expression in ALL might reflect the co-existence
of genetically distinct sub-populations, generated early during
oncogenesis possibly due to genomic instability. However, in
the patients analyzed here, the immunophenotypic differences
Figure 2 Diagram of the experimental workflow and the results from FISH and Ig/TCR gene rearrangement analyses in flow-sorted cell
populations. A total of 41 leukemic-cell populations were sorted. Of these, 37 were analyzed by PCR, 29 were analyzed by FISH and 25 were
analyzed by both PCR and FISH. In all, 12 normal cell populations were sorted. Of these, 12 were analyzed by PCR, 6 were analyzed by FISH and
6 were analyzed by both PCR and FISH.
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were, in most cases, not related to differences in the immune
gene-rearrangement profiles. Thus, these populations must have
evolved from a common clonal origin, and the rearrangement
process must have been completed early in the common
progenitor cell. Consequently, possible genomic differences
must be at loci other than the Ig/TCR genes, or might involve
epigenetic differences, for example, DNA methylation and
chromatin remodeling.
In conclusion, immunophenotypically distinct sub-popula-
tions are common at diagnosis in BCP-ALL. Occasionally,
leukemic sub-populations may lack the dominating PCR MRD
marker, which could result in underestimation of MRD, the risk
of which may be reduced by the use of several independent PCR
markers. Furthermore, awareness of the sub-populations is
important in flow-cytometric MRD monitoring to avoid under-
estimation of residual disease.
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Donor KIR haplotype B improves progression-free and overall survival after allogeneic
hematopoietic stem cell transplantation for multiple myeloma
Leukemia (2011) 25, 1657–1661; doi:10.1038/leu.2011.138;
published online 7 June 2011
Allogeneic hematopoietic stem cell transplantation from related
or unrelated donor has become a standard treatment for many
patients with hematological malignancies, but the role of this
treatment approach in the treatment of multiple myeloma
remains controversial, as high risk of relapse remains a major
concern.1 In acute leukemias, especially acute myeloid leuke-
mias, alloreactive donor-derived natural killer cells (NK cells)
have been correlated with an improved survival, especially after
T-cell-depleted transplant procedures such as haploidentical
stem cell transplantation.2 Small reports after allogeneic stem
cell transplantation for multiple myeloma as well as pre-clinical
models showed that alloreactive NK cells might have a role
regarding cytotoxicity and relapse prevention in multiple
myeloma.3 The NK cell function is determined by several
receptor families including activating and inhibitory killer
cell immunoglobulin-like receptors (KIRs). For the majority,
especially for the active KIRs, the correspondent ligands are
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